Efficacy of vaccination with a combination of Leishmania amastigote antigens and the lipid A-analogue ONO-4007 for immunoprophylaxis and immunotherapy against Leishmania amazonensis infection in a murine model of New World cutaneous leishmaniasis

Vaccine

Volumn 24, Issue 27-28, 2006, Pages 5645-5652

  Calvopina, Manuel ^a   Barroso, Paola A ^a   Marco, Jorge D ^a   Korenaga, Masataka ^a   Cooper, Philip J ^b,c   Nonaka, Shigeo ^d   Hashiguchi, Yoshihisa ^a  

^a KOCHI UNIVERSITY   (Japan)

^b Hospital Pedro Vicente Maldonado   (Ecuador)

^c ST GEORGE'S UNIVERSITY OF LONDON   (United Kingdom)

^d UNIVERSITY OF THE RYUKYUS   (Japan)

Author keywords

Adjuvants; Leishmaniasis; ONO 4007; Vaccine

Indexed keywords

2 DEOXY 3 O (9 PHENYLNONANOYL) 2 [3 (9 PHENYLNONANOYLOXY) TETRADECANOYLAMINO]GLUCOPYRANOSE 4 SULFATE; 2 DEOXY 3 O (9 PHENYLNONANOYL) 2 [3 (9 PHENYLNONANOYLOXY)TETRADECANOYLAMINO]GLUCOPYRANOSE 4 SULFATE; ANTIGEN; CYTOKINE; GAMMA INTERFERON; INTERLEUKIN 12; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; CYTOKINE PRODUCTION; DRUG EFFICACY; FEMALE; IMMUNOPROPHYLAXIS; IMMUNOTHERAPY; LEISHMANIA; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTECTION; SKIN LEISHMANIASIS; TREATMENT OUTCOME; VACCINATION;

ANIMALS; ANTIGENS, PROTOZOAN; DISEASE MODELS, ANIMAL; FEMALE; INTERFERON TYPE II; INTERLEUKIN-12; LEISHMANIA; LEISHMANIASIS, CUTANEOUS; LIPID A; MICE; MICE, INBRED BALB C; PROTOZOAN VACCINES;

EID: 33745001227     PISSN: 0264410X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.vaccine.2006.03.023     Document Type: Article

References (60)

1. TDR/WHO, Scientific Working Group. Report on Leishmaniasis TDR/SWG/04. Geneva, Switzerland; 2004. p. 1-137.
2. Croft SL. Drug resistance in leishmaniasis. Scientific Working Group. Report on leishmaniasis TDR/SWG/04. Geneva, Switzerland; 2004. p. 108-19.
3. Campos-Neto A. Anti-leishmania vaccine. In: Farrel J.P. (Ed). World class parasites. Leishmania vol. 4 (2002), Kluwer Academic Publishers, USA 169-190
4. Handman E. Leishmaniasis: current status of vaccine development. Clin Microbiol Rev (2001) 229-243
5. Handman E., Noormohammadi A.H., Curtis J.M., Baldwin T., and Sjolander A. Therapy of murine cutaneous leishmaniasis by DNA vaccination. Vaccine 18 (2000) 3011-3017
6. Santos W.R., Aguiar I.A., Paraguai S.E., Lima V.M.F., Palatnik M., and Palatnik S.C.B. Immunotherapy against murine experimental visceral leishmaniasis with the FML-vaccine. Vaccine 21 (2003) 4668-4676
7. Borja-Cabrera G.P., Cruz M.A., Paraguai de Souza E., Hashimoto O.L.Y., de A., Trivellato F.A., et al. Effective immunotherapy against canine visceral leishmaniasis with the FML-vaccine. Vaccine 22 (2004) 2234-2243
8. Convit J., Rondon A., Urlich M., Bloom B., Castellanos P.L., Pinardi M.E., et al. Immunotherapy versus chemotherapy in localised cutaneous leishmaniasis. Lancet (1987) 401-404
9. Convit J., Urlich M., Polegre M.A., Avila A., Rodriguez N., Mazzedo M.I., et al. Therapy of Venezuelan patients with severe mucocutaneous or early lesions of diffuse cutaneous leishmaniasis with a vaccine containing pasteurized Leishmania promastigotes and Bacillus Calmette-Guerin-preliminary report. Mem Inst Oswaldo Cruz 99 (2004) 57-62
10. Mayrink W., Magalhaes P.A., Michalick M.S., da Costa C.A., Lima A., de O., et al. Immunotherapy as a treatment of American cutaneous leishmaniasis: preliminary studies in Brazil. Parassitologia 34 (1992) 159-165
11. Machado-Pinto J., Pinto J., da Costa C.A., Genaro O., Marques M.J., Madabber F., et al. Immunochemotherapy for cutaneous leishmaniasis: a controlled trial using killed Leishmania (Leishmania) amazonensis vaccine plus antimonial. Int J Dermatol 41 2 (2002) 73-78
12. Badaro R., Lobo I., Nakatani M., Muinos A., Netto E.M., Coler R.N., et al. Successful use of a defined antigen/GM-CSF adjuvant vaccine to treat mucosal leishmaniasis refractory to antimony: a case report. Braz J Infect Dis 5 (2001) 223-232
13. Coler R.N., and Reed S.G. Second-generation vaccines against leishmaniasis. Trends Parasitol 21 (2005) 244-249
14. Vanloubbeeck Y., and Jones D.E. The immunology of Leishmania infection and the implications for vaccine development. Ann N Y Acad Sci 1026 (2004) 267-272
15. Cluff C.W., Baldridge J.R., Stover A.G., Evans J.T., Johnson D.A., Lacy M.J., et al. Synthetic toll-like receptor 4 agonists stimulate innate resistance to infectious challenge. Infect Immun 73 (2005) 3044-3052
16. Yang D., Sato M., Ueda H., Tsukagoshi S., and Yamazaki M. Activation of tumor-infiltrating macrophages by a synthetic lipid A analog (ONO-4007) and its implication in antitumor effects. Cancer Immunol Immunother 38 (1994) 287-293
17. Hattori Y., Szabo C., Gross S., Thiemermann C., and Vane J.R. Lipid A and the lipid A analogue anti-tumour compound ONO-4007 induce nitric oxide synthase in vitro and in vivo. Eur J Pharmacol 291 (1995) 83-90
18. Matsumoto N., Aze Y., Akimoto A., and Fujita T. Restoration of immune response in tumor-bearing mice by ONO-4007, an antitumor lipid A derivative. Immunopharmacology 36 (1997) 69-78
19. Matsushita K., Kuramitsu Y., Ohiro Y., Kobayashi I., Watanabe T., Kobayashi M., et al. ONO-4007, a synthetic lipid A analog, induce Th1-type immune response in tumor eradication and restores nitric oxide production by peritoneal macrophages. Int J Oncol 23 2 (2003) 489-493
20. Takiguchi K., Nakamoto T., Inagawa H., Kohchi C., Nishizawa T., Nagasue N., et al. Profile of cytokines produced in tumor tissue after administration of cyclophosphamide in a combination therapy with tumor necrosis factor. Anticancer Res 24 (2004) 1823-1828
21. Kaisho T., and Akira S. Toll-like receptors as adjuvant receptors. Biochem Biophys Acta 1589 (2002) 1-13
22. Tamai R., Asai Y., Hashimoto M., Fukase K., Kusumoto S., Ishida H., et al. Cell activation by monosaccharide lipid A analogues utilizing Toll-like receptor 4. Immunology 110 (2003) 66-72
23. Khan M.A.K., Maruno M., Khaskhely N.M., Ramzi S.T., Hosokawa A., Uezato H., et al. Inhibition of intracellular proliferation of Leishmania parasites in vitro and suppression of skin lesion development in BALB/c mice by a novel lipid A analog (ONO-4007). Am J Trop Med Hyg 67 (2002) 184-190
24. McMahon-Pratt D., and Alexander J. Does the Leishmania major paradigm of pathogenesis and protection hold for New World cutaneous leishmaniasis or the visceral disease?. Immunol Rev 201 (2004) 206-224
25. Ji J., Sun J., and Soong L. Impaired expression of inflammatory cytokines and chemokines at early stages of infection with Leishmania amazonensis. Infect Immun 71 (2003) 4278-4288
26. McMahon-Pratt D. Mechanisms of pathogenesis and vaccines. Report of the fourth TDR/IDRI meeting on second-generation vaccines against leishmaniasis TDR/PRD/LEISH/VAC/01.1. Yucatan, Mexico; 2001. p. 1-13.
27. Farrel J.P. The immunology of cutaneous leishmaniasis: experimental infections and human disease. In: Farrel J.P. (Ed). World class parasites. Leishmania vol. 4 (2002), Kluwer Academic Publishers, USA 151-168
28. Chang K.P. Human cutaneous Leishmania in a mouse macrophage line: propagation and isolation of intracellular parasites. Science 209 (1980) 1240-1242
29. Valli L.C., Passos V.M., Dietze R., Callahan H.L., Berman J.D., and Grogl M. Humoral immune responses among mucosal and cutaneous leishmaniasis patients caused by Leishmania braziliensis. J Parasitol 85 6 (1999) 1076-1083
30. Afonso L.C.C., Scharton T.M., Vieira L.W., Wysocka M., Trichieri G., and Scott P. The adjuvant effect of interleukin-12 in a vaccine against Leishmania major. Science 263 (1994) 235-237
31. Walker P.S., Scharton-Kersten T., Krieg A.M., Love-Homan L., Rowton E.D., Udey M.C., et al. Immunostimulatory oligodeoxynucleotides promote protective immunity and provide systemic therapy for leishmaniasis via IL-12 and IFN-γ-dependent mechanisms. Proc Natl Acad Sci USA 96 (1999) 6970-6975
32. Evans D. Handbook on isolation characterization and cryopreservation of Leishmania (1989), TDR/UNDP/World Bank/WHO, Geneva, Switzerland
33. TDR/IDRI. Report of the fourth TDR/IDRI Meeting on second-generation vaccines against Leishmaniasis TDR/PRD/LEISH/VAC/01.1. Yucatan, Mexico; 2001. p. 1-13.
34. Champsi J., and McMahon-Pratt D. Membrane glycoprotein M-2 protects against Leishmania amazonensis infection. Infect Immun 56 (1988) 3272-3279
35. Pinto E.F., de Mello Cortezia M., and Rossi-Bergmann B. Interferon-gamma-inducing oral vaccination with Leishmania amazonensis antigens protect BALB/c and C57BL/6 mice against cutaneous leishmaniasis. Vaccine 21 (2003) 3534-3541
36. Vanloubbeeck Y.F., and Jones D.E. Protection of C3HEB/FEJ mice against Leishmania amozonensis challenge after previous Leishmania major infection. Am J Trop Med Hyg 71 (2004) 407-411
37. Armijos R.X., Weigel M.M., Calvopina M., Hidalgo A., Cevallos W., and Correa J. Safety, immunogenicity, and efficacy of an autoclaved Leishmania amazonensis vaccine plus BCG adjuvant against New World cutaneous leishmaniasis. Vaccine 22 (2004) 1320-1326
38. Velez I.D., Gilchrist K., Arbelaez M.P., Rojas C.A., Puerta J.A., Antunes C.M.F., et al. Failure of a killed Leishmania amazonensis vaccine against American cutaneous leishmaniasis in Colombia. Trans R Soc Trop Med Hyg 99 (2005) 593-598
39. Aebischer T. Subunit vaccination against cutaneous leishmaniasis: what is to be learned from murine models. Report of the fourth TDR/IDRI meeting on second-generation vaccines against leishmaniasis TDR/PRD/LEISH/VAC/01.1. Yucatan, Mexico; 2001. p. 1-13.
40. Liew F.Y., Li Y., and Millott S. Tumor necrosis factor-alfa synergizes with IFN-gamma in mediating killing of Leishmania major though the induction of nitric oxide. J Immunol 145 (1990) 4306-4310
41. Drapier J.C., Wietzerbin J., and Hibbs Jr. J.B. Interferon-gamma and tumor necrosis factor induce the l-arginine-dependent cytotoxic effector mechanism in murine macrophages. Eur J Immunol 18 10 (1988) 1857-1892
42. Roach T.I., Kiderlen A.F., and Blackwell J.M. Role of inorganic nitrogen oxides and tumor necrosis factor alpha in killing Leishmania donovani amastigotes in gamma interferon-lipopolysaccharide-activated macrophages from Lshs and Lshr congenic mouse strains. Infect Immun 59 11 (1991) 3935-3944
43. Qi H., Ji J., Wanasen N., and Soong L. Enhanced replication of Leishmania amazonensis amastigotes in gamma interferon-stimulated murine macrophages: implications for the pathogenesis of cutaneous leishmaniasis. Infect Immun 72 (2004) 988-995
44. Pashine A., Valiante N.M., and Ulmer J.B. Targeting the innate immune response with improved vaccine adjuvants. Nat Med 11 4 (2005) S63-S68
45. Persing D.H., Coler R.N., Lacy M.J., Johnson D.A., Baldridge J.R., Hershberg R.M., et al. Taking toll: lipid A mimetics as adjuvants and immunomodulators. Trends Microbiol 10 Suppl. (2002) S32-S37
46. Inagawa H., Nishizawa T., Honda T., Nakamoto T., Takagi K., and Soma G. Mechanisms by which chemotherapeutics agents augment the antitumor effects of tumor necrosis factor: involvement of the pattern shift of cytokines from Th2 to Th1 in tumor lesions. Anticancer Res 18 5D (1998) 3957-3964
47. Barral-Neto M., Barral A., Brownell C.E., Skeiky Y.A.W., Ellingsworth L.R., Twardzik D.R., et al. Transforming growth factor-b in leishmanial infection: a parasite escape mechanism. Science 257 (1992) 545-548
48. Olmo P.R., Fonseca P.E., Ribeiro C.L.J., Matos G.H.L., Ferro F.R., and Rossi-Bergmann B. TGF-B-associated enhanced susceptibility to leishmaniasis following intramuscular vaccination of mice with Leishmania amazonensis antigens. Microb Infect 7 (2005) 1317-1323
49. Barral-Netto M. Differences in IFN-γ production in vitro predict the pace of in vivo anti-leishmania responses in normal volunteers. Report of the fourth TDR/IDRI meeting on second-generation vaccines against leishmaniasis TDR/PRD/LEISH/VAC/01.1. Yucatan, Mexico; 2001. p. 1-13.
50. Van Weyenbergh J., P Silva M.P., Bafica A., Cardoso S., Wietzerbin J., and Barral-Neto M. IFN-beta and TGF-beta differentially regulate IL-12 activity in human peripheral blood mononuclear cells. Immunol Lett 75 2 (2001) 117-122
51. Jones D.E., Elloso M.M., Showe L., Williams D., Trinchieri G., and Scott P. Differential regulation of the interleukin-12 receptor during the innate immune response to Leishmania major. Infect Immun 66 (1998) 3818-3824
52. Sypek J.P., Chung C.L., Mayor S.H.E., Subramanyam J.M., Goldman S.J., Sieburth D.S., et al. Resolution of cutaneous leishmaniasis: interleukin 12 initiates a protective T helper type 1 immune response. J Exp Med 177 (1993) 1797-1802
53. Yamakami K., Akao S., Sato M., Nitta Y., Miyazaki J., and Tadakuma T. A single intradermal administration of soluble leishmanial antigens and plasmid expressing interleukin-12 protects BALB/c mice from Leishmania major infection. Parasitol Int 50 (2001) 81-91
54. Jones D.E., Buxbaum L.U., and Scott P. IL-4-independent inhibition of IL-12 responsiveness during Leishmania amazonensis infection. J Immunol 165 (2000) 364-372
55. McPherson G.G., Jenkins C.D., Stein M.J., and Edwards C. Endotoxic-mediated dendritic cell release from the intestine: characterization of released dendritic cells and TNF dependence. J Immunol 154 (1995) 1317-1322
56. Qi H., Denning T.L., and Soong L. Differential induction of interleukin-10 and interleukin-12 in dendritic cells by microbial Toll-like receptor activators and skewing of T-cell cytokine profiles. Infect Immun 71 6 (2003) 3337-3342
57. Iio J., Katamura K., Takeda H., Ohmura K., Yasumi T., Meguro T.A., et al. Lipid A analogue, ONO-4007, inhibit IgE response and antigen-induced eosinophilic recruitment into airways in BALB/c mice. Int Arch Allergy Immunol 127 3 (2002) 217-225
58. Coler R.N., Skeiky Y.A.W., Bernards K., Greeson K., Carter D., Cornellison C.D., et al. Immunization with a polyprotein vaccine consisting of the T-cell antigens Thiol-specific antioxidant, Leishmania major stress-inducible protein 1, and Leishmania elongation initiation factor protects against leishmaniasis. Infect Immun 70 8 (2002) 4215-4225
59. + T cell responses and protection against Leishmania major infection. J Exp Med 195 (2002) 1565-1573
60. de Bono J.S., Dalgleish A.G., Carmichael J., Diffley J., Lofts F.J., Fyffe D., et al. Phase I study of ONO-4007, a synthetic analogue of the lipid A moiety of bacterial lipopolysaccharide. Clin Cancer Res 6 (2000) 397-405